In search of determinants of therapeutic response to CD19-directed CAR-T cells in patients with chronic lymphocytic leukemia (CLL), a study evaluated the genomic and phenotypic features of the cells infused. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.